AngioDynamics Valuation
| ANGO Stock | USD 10.98 0.01 0.09% |
At this time, the firm appears to be undervalued. AngioDynamics shows a prevailing Real Value of $13.16 per share. The current price of the firm is $10.98. Our model approximates the value of AngioDynamics from analyzing the firm fundamentals such as return on equity of -0.15, and Profit Margin of (0.09) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting AngioDynamics' valuation include:
Price Book 2.5665 | Enterprise Value | Enterprise Value Ebitda 127.0175 | Price Sales 1.4714 | Forward PE 96.1538 |
Undervalued
Today
Please note that AngioDynamics' price fluctuation is not too volatile at this time. Calculation of the real value of AngioDynamics is based on 3 months time horizon. Increasing AngioDynamics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AngioDynamics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AngioDynamics Stock. However, AngioDynamics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.98 | Real 13.16 | Target 19.33 | Hype 10.99 |
The intrinsic value of AngioDynamics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AngioDynamics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AngioDynamics helps investors to forecast how AngioDynamics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AngioDynamics more accurately as focusing exclusively on AngioDynamics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use AngioDynamics' intrinsic value based on its ongoing forecasts of AngioDynamics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against AngioDynamics' closest peers.
AngioDynamics Cash |
|
AngioDynamics Revenue by Product
AngioDynamics Total Value Analysis
AngioDynamics is presently forecasted to have valuation of 412.81 M with market capitalization of 452.15 M, debt of 3.95 M, and cash on hands of 24.56 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the AngioDynamics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
412.81 M | 452.15 M | 3.95 M | 24.56 M |
AngioDynamics Investor Information
About 12.0% of the company shares are held by company insiders. The book value of AngioDynamics was presently reported as 4.24. The company has Price/Earnings To Growth (PEG) ratio of 1.87. AngioDynamics recorded a loss per share of 0.67. The entity had not issued any dividends in recent years. Based on the key indicators related to AngioDynamics' liquidity, profitability, solvency, and operating efficiency, AngioDynamics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.AngioDynamics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AngioDynamics has an asset utilization ratio of 104.41 percent. This suggests that the Company is making $1.04 for each dollar of assets. An increasing asset utilization means that AngioDynamics is more efficient with each dollar of assets it utilizes for everyday operations.AngioDynamics Profitability Analysis
Based on AngioDynamics' profitability indicators, AngioDynamics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess AngioDynamics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2001-08-31 | Previous Quarter -10.9 M | Current Value -6.3 M | Quarterly Volatility 26 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.58 | 0.62 |
|
|
For AngioDynamics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of AngioDynamics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well AngioDynamics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between AngioDynamics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of AngioDynamics over time as well as its relative position and ranking within its peers.
AngioDynamics Earnings per Share Projection vs Actual
The next projected EPS of AngioDynamics is estimated to be -0.0725 with future projections ranging from a low of -0.0825 to a high of -0.065. AngioDynamics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.67. Please be aware that the consensus of earnings estimates for AngioDynamics is based on EPS before non-recurring items and includes expenses related to employee stock options.AngioDynamics Earnings Estimation Breakdown
The calculation of AngioDynamics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of AngioDynamics is estimated to be -0.0725 with the future projection ranging from a low of -0.0825 to a high of -0.065. Please be aware that this consensus of annual earnings estimates for AngioDynamics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.08 Lowest | Expected EPS | -0.07 Highest |
AngioDynamics Earnings Projection Consensus
Suppose the current estimates of AngioDynamics' value are higher than the current market price of the AngioDynamics stock. In this case, investors may conclude that AngioDynamics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and AngioDynamics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of May 2026 | Current EPS (TTM) | |
| 3 | 32.74% | 0.0 | -0.0725 | -0.67 |
AngioDynamics Ownership Allocation
AngioDynamics holds a total of 41.22 Million outstanding shares. The majority of AngioDynamics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AngioDynamics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AngioDynamics. Please pay attention to any change in the institutional holdings of AngioDynamics as this could imply that something significant has changed or is about to change at the company. Also note that nearly four million five hundred seventy-one thousand eight invesors are currently shorting AngioDynamics expressing very little confidence in its future performance.AngioDynamics Profitability Analysis
The company reported the previous year's revenue of 292.5 M. Net Loss for the year was (33.99 M) with profit before overhead, payroll, taxes, and interest of 167.72 M.About AngioDynamics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of AngioDynamics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AngioDynamics based exclusively on its fundamental and basic technical indicators. By analyzing AngioDynamics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of AngioDynamics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of AngioDynamics. We calculate exposure to AngioDynamics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AngioDynamics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 181.4 M | 128.5 M | |
| Pretax Profit Margin | (0.12) | (0.13) | |
| Operating Profit Margin | (0.16) | (0.15) | |
| Net Loss | (0.12) | (0.13) | |
| Gross Profit Margin | 0.62 | 0.58 |
AngioDynamics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 41 M | |
| Forward Price Earnings | 96.1538 |
AngioDynamics Current Valuation Indicators
AngioDynamics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final AngioDynamics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as AngioDynamics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use AngioDynamics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes AngioDynamics' worth.When determining whether AngioDynamics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AngioDynamics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Angiodynamics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Angiodynamics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Health Care Equipment & Supplies sector continue expanding? Could AngioDynamics diversify its offerings? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AngioDynamics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.67) | Revenue Per Share | Quarterly Revenue Growth 0.09 | Return On Assets | Return On Equity |
Investors evaluate AngioDynamics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating AngioDynamics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause AngioDynamics' market price to deviate significantly from intrinsic value.
Understanding that AngioDynamics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AngioDynamics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, AngioDynamics' market price signifies the transaction level at which participants voluntarily complete trades.